Symposium

[S44] Sphingolipid biology and therapy

Mon. Mar 29, 2021 3:45 PM - 5:45 PM [Room I] Oral Presentation I (Online)

Organizer: Kitatani Kazuyuki (Fac. Pharm. Sci, Setsunan Univ.), Nakamura Hiroyuki (Grad Sch Pharm Sci, Chiba Univ)

Sphingolipids have been emerging as bioactive lipids that modulate cell signaling pathways and biological responses. Over 30 enzymes are involved in the sphingolipid metabolism, generating >200 structurally distinct sphingolipids. Among them, ceramide, glycosphingolipids, sphingosine-1-phosphate, and sphingomyelin are well-studied and those link the sphingolipid metabolism to human diseases including infectious diseases, insulin resistance, obese, neurodegenerative diseases, cardiovascular diseases, lysosomal diseases, and cancer. However, emerging evidence points dramatic complexities in sphingolipid metabolism and signaling. The research field of bioactive sphingolipids still faces challenges in the molecular underpinnings, including defining the molecular mechanisms of pathway and enzyme regulation, lipid-protein interaction, and therapeutic approaches. In this section, we discuss the latest advances in sphingolipid life science and its-based therapy for human diseases.

+Add all to schedule

Opening remarks: Hiroyuki Nakamura (Grad. Sch. Pharm. Sci., Chiba Univ.) (3:45 PM - 3:50 PM)

3:50 PM - 4:05 PM

[S44-1] Sphingolipid metabolism in Niemann-Pick disease type C and drug discovery

○Hiroyuki Nakamura¹, Takuya Honda¹, Kazuyuki Yamagata^1,2, Wado Akamatsu³, Takahiro Shiga³, Haruaki Ninomiya⁴, Toshihiko Murayama¹ (1. Grad. Sch. Pharm. Sci., Chiba Univ., 2. Grad. Sch. Med., Chiba Univ., 3. Sch. Med., Juntendo Univ., 4. Fac. Med., Tottori Univ.)

4:05 PM - 4:25 PM

[S44-2] Application of genome editing technologies to studies on sphingolipid biology

○Toshiyuki Yamaji¹ (1. Dept. Biochem. Cell Biol., NIID)

4:25 PM - 4:45 PM

[S44-3] Glycosphingolipids in central and peripheral leptin signaling

○Kei-ichiro Inamori¹ (1. Inst. Mol. Biomembr. Glycobiol., Tohoku Med. Pharm. Univ.)

4:45 PM - 5:05 PM

[S44-4] Neutral sphingomyelinase 2 heightens anti-melanoma immune response and anti-PD-1 therapy efficacy.

○Bruno Segui^1,2 (1. Fac. Pharm. Sci., Paul Sabatier Univ.-Toulouse III, France, 2. Cancer Res. Center Toulouse, France)

5:05 PM - 5:25 PM

[S44-5] Ceramide/sphingomyelin balance regulated by sphingomyelin synthase in murine disease models

○Makoto Taniguchi¹ (1. Med. Res. Inst., Kanazawa Med. Univ.)

5:25 PM - 5:40 PM

[S44-6] Roles for sphingolipids in programmed necrosis and cancer therapy.

○Kazuyuki Kitatani¹ (1. Fac. Pharm. Sci, Setsunan Univ.)

Closing remarks: Kazuyuki Kitatani (Fac. Pharm. Sci, Setsunan Univ.) (5:40 PM - 5:45 PM)

Session information